BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND KMT2C, ENSG00000055609, MLL3, 58508
21 results:

  • 1. CRISPR/Cas9 model of prostate cancer identifies kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
    Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
    Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Germline variants in early and late-onset Brazilian prostate cancer patients.
    Coelho KBCA; Squire JA; Duarte KG; Sares CTG; Moreda NA; Pereira JL; da Silva IT; Defelicibus A; Aoki MN; Rivas JL; Dos Reis RB; Zanette DL
    Urol Oncol; 2024 Mar; 42(3):68.e11-68.e19. PubMed ID: 38311546
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
    Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
    Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic mutations in smoking-associated prostate cancer.
    Elshafei A; Al-Toubat M; Feibus AH; Koul K; Jazayeri SB; Lelani N; Henry V; Balaji KC
    Prostate; 2023 Sep; 83(13):1229-1237. PubMed ID: 37455402
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Mutations in epigenetic regulator
    Zhu S; Xu N; Liang J; Zhao F; Wang Z; Ni Y; Dai J; Zhao J; Zhang X; Chen J; Sun G; Shen P; Zeng H
    Oncol Res; 2023; 31(4):605-614. PubMed ID: 37415738
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of prostate cancer.
    Zhang P; An Z; Sun C; Xu Y; Zhang Z
    Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. kmt2c methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
    Limberger T; Schlederer M; Trachtová K; Garces de Los Fayos Alonso I; Yang J; Högler S; Sternberg C; Bystry V; Oppelt J; Tichý B; Schmeidl M; Kodajova P; Jäger A; Neubauer HA; Oberhuber M; Schmalzbauer BS; Pospisilova S; Dolznig H; Wadsak W; Culig Z; Turner SD; Egger G; Lagger S; Kenner L
    Mol Cancer; 2022 Mar; 21(1):89. PubMed ID: 35354467
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Histone methyltransferase kmt2c plays an oncogenic role in prostate cancer.
    Lian J; Xu C; Chen X; Huang S; Wu D
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1627-1640. PubMed ID: 35322299
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast cancer Throughout Disease Progression.
    Bos MK; Smid M; Sleijfer S; Martens JWM
    JCO Precis Oncol; 2022 Jan; 6():e2100190. PubMed ID: 35050709
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. What Do We Have to Know about PD-L1 Expression in prostate cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
    Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
    Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Distinct Genomic Alterations in prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Mutational and transcriptomic landscapes of a rare human prostate basal cell carcinoma.
    Su X; Long Q; Bo J; Shi Y; Zhao LN; Lin Y; Luo Q; Ghazanfar S; Zhang C; Liu Q; Wang L; He K; He J; Cui X; Yang JYH; Han ZG; Yang G; Sha JJ
    Prostate; 2020 May; 80(6):508-517. PubMed ID: 32119131
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract] [Full Text] [Related]  

  • 16.
    Kim SH; Park WS; Chung J
    Investig Clin Urol; 2019 May; 60(3):148-155. PubMed ID: 31098421
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. mll3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
    Xiong W; Deng H; Huang C; Zen C; Jian C; Ye K; Zhong Z; Zhao X; Zhu L
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):454-463. PubMed ID: 30385408
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection.
    Park ES; Yan JP; Ang RA; Lee JH; Deng X; Duffy SP; Beja K; Annala M; Black PC; Chi KN; Wyatt AW; Ma H
    Lab Chip; 2018 Jun; 18(12):1736-1749. PubMed ID: 29762619
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
    Katoh M
    Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The mitochondrial and autosomal mutation landscapes of prostate cancer.
    Lindberg J; Mills IG; Klevebring D; Liu W; Neiman M; Xu J; Wikström P; Wiklund P; Wiklund F; Egevad L; Grönberg H
    Eur Urol; 2013 Apr; 63(4):702-8. PubMed ID: 23265383
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.